CC BY 4.0 · Glob Med Genet 2021; 08(03): 083-084
Single-Cell Profiling Explore the Immunologic Mechanisms of Tumor Relapse in Hepatocellular Carcinoma
Liyi Zhang
1
State Key Laboratory of Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China
› Institutsangaben
References
1
Sung H,
Ferlay J,
Siegel RL.
et al.
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
2
Cao M,
Li H,
Sun D,
Chen W.
Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020; 40 (05) 205-210
3
Feng RM,
Zong YN,
Cao SM,
Xu RH.
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?. Cancer Commun (Lond) 2019; 39 (01) 22
4
Singal AG,
Lampertico P,
Nahon P.
Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020; 72 (02) 250-261
5
Zheng J,
Kuk D,
Gönen M.
et al.
Actual 10-year survivors after resection of hepatocellular carcinoma. Ann Surg Oncol 2017; 24 (05) 1358-1366
6
Rossi JF,
Céballos P,
Lu ZY.
Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. Cancer Commun (Lond) 2019; 39 (01) 34
7
Wu T,
Wu X,
Wang HY,
Chen L.
Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Commun (Lond) 2019; 39 (01) 21
8
Zheng C,
Zheng L,
Yoo JK.
et al.
Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 2017; 169 (07) 1342-1356.e16
9
Sun Y,
Wu L,
Zhong Y.
et al.
Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell 2021; 184 (02) 404-421.e16
10
Ding X,
He M,
Chan AWH.
et al.
Genomic and epigenomic features of primary and recurrent hepatocellular carcinomas. Gastroenterology 2019; 157 (06) 1630-1645.e6
11
Chiossone L,
Dumas PY,
Vienne M,
Vivier E.
Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 2018; 18 (11) 671-688
12
Obar JJ,
Jellison ER,
Sheridan BS.
et al.
Pathogen-induced inflammatory environment controls effector and memory CD8+ T cell differentiation. J Immunol 2011; 187 (10) 4967-4978
13
Amsen D,
van Gisbergen KPJM,
Hombrink P,
van Lier RAW.
Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol 2018; 19 (06) 538-546
14
Chen L.
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4 (05) 336-347
15
Butte MJ,
Keir ME,
Phamduy TB,
Sharpe AH,
Freeman GJ.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27 (01) 111-122
